Cholinergic Antagonists and Behavioral Disturbances in Neurodegenerative Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Apr 28

PMID 37108085

Authors

Rachid Mahmoudi

Jean Luc Novella

Sarah Laurent-Badr

Sarah Boulahrouz

David Tran

Isabella Morrone

Yacine Jaidi

Affiliations

Soon will be listed here.

Abstract

Cholinergic antagonists interfere with synaptic transmission in the central nervous system and are involved in pathological processes in patients with neurocognitive disorders (NCD), such as behavioral and psychological symptoms of dementia (BPSD). In this commentary, we will briefly review the current knowledge on the impact of cholinergic burden on BPSD in persons with NCD, including the main pathophysiological mechanisms. Given the lack of clear consensus regarding symptomatic management of BPSD, special attention must be paid to this preventable, iatrogenic condition in patients with NCD, and de-prescription of cholinergic antagonists should be considered in patients with BPSD.

Citing Articles

Anticholinergic burden and behavioral and psychological symptoms in older patients with cognitive impairment.

Pistorio S, Scotto di Tella G, Canzanella V, Merenda R, Cuomo G, Iacotucci P Front Med (Lausanne). 2025; 12:1505007.

PMID: 40012975 PMC: 11861190. DOI: 10.3389/fmed.2025.1505007.

Growth Factors and Their Application in the Therapy of Hereditary Neurodegenerative Diseases.

Issa S, Fayoud H, Shaimardanova A, Sufianov A, Sufianova G, Solovyeva V Biomedicines. 2024; 12(8).

PMID: 39200370 PMC: 11351319. DOI: 10.3390/biomedicines12081906.

Molecular Mechanisms of Dementia.

Cantone M Int J Mol Sci. 2023; 24(17).

PMID: 37685834 PMC: 10487875. DOI: 10.3390/ijms241713027.

References

McKeith I, Cummings J . Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol. 2005; 4(11):735-42. DOI: 10.1016/S1474-4422(05)70219-2. View

Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G . Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res. 1989; 477(1-2):90-9. DOI: 10.1016/0006-8993(89)91396-6. View

Cancelli I, Valentinis L, Merlino G, Valente M, Gigli G . Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer's disease. Clin Pharmacol Ther. 2007; 84(1):63-8. DOI: 10.1038/sj.clpt.6100435. View

Colloby S, Pakrasi S, Firbank M, Perry E, Piggott M, Owens J . In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. Neuroimage. 2006; 33(2):423-9. DOI: 10.1016/j.neuroimage.2006.07.026. View

Medeiros R, Kitazawa M, Caccamo A, Baglietto-Vargas D, Estrada-Hernandez T, Cribbs D . Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. Am J Pathol. 2011; 179(2):980-91. PMC: 3157199. DOI: 10.1016/j.ajpath.2011.04.041. View

Wang S, Zhu S, Mash D, El-Fakahany E . Comparison of the concentration of messenger RNA encoding four muscarinic receptor subtypes in control and Alzheimer brains. Brain Res Mol Brain Res. 1992; 16(1-2):64-70. DOI: 10.1016/0169-328x(92)90194-g. View

Campbell N, Ayub A, Boustani M, Fox C, Farlow M, Maidment I . Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis. Clin Interv Aging. 2009; 3(4):719-28. PMC: 2682404. DOI: 10.2147/cia.s4250. View

Dauphinot V, Mouchoux C, Veillard S, Delphin-Combe F, Krolak-Salmon P . Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders. Alzheimers Res Ther. 2017; 9(1):58. PMC: 5540419. DOI: 10.1186/s13195-017-0284-4. View

Shirey J, Brady A, Jones P, Davis A, Bridges T, Kennedy J . A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci. 2009; 29(45):14271-86. PMC: 2811323. DOI: 10.1523/JNEUROSCI.3930-09.2009. View

10.

Finkel S, Costa E Silva J, Cohen G, Miller S, Sartorius N . Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996; 8 Suppl 3:497-500. DOI: 10.1017/s1041610297003943. View

11.

Watanabe S, Fukatsu T, Kanemoto K . Risk of hospitalization associated with anticholinergic medication for patients with dementia. Psychogeriatrics. 2018; 18(1):57-63. DOI: 10.1111/psyg.12291. View

12.

Tan E, Eriksdotter M, Garcia-Ptacek S, Fastbom J, Johnell K . Anticholinergic Burden and Risk of Stroke and Death in People with Different Types of Dementia. J Alzheimers Dis. 2018; 65(2):589-596. DOI: 10.3233/JAD-180353. View

13.

Cummings J, Kaufer D . Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology. 1996; 47(4):876-83. DOI: 10.1212/wnl.47.4.876. View

14.

Swartz R, Sahlas D, Black S . Strategic involvement of cholinergic pathways and executive dysfunction: Does location of white matter signal hyperintensities matter?. J Stroke Cerebrovasc Dis. 2007; 12(1):29-36. DOI: 10.1053/jscd.2003.5. View

15.

Jester D, Molinari V, Zgibor J, Volicer L . Prevalence of psychotropic polypharmacy in nursing home residents with dementia: a meta-analysis. Int Psychogeriatr. 2021; 33(10):1083-1098. DOI: 10.1017/S1041610220004032. View

16.

Shiozaki K, Iseki E, Uchiyama H, Watanabe Y, Haga T, Kameyama K . Alterations of muscarinic acetylcholine receptor subtypes in diffuse lewy body disease: relation to Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1999; 67(2):209-13. PMC: 1736504. DOI: 10.1136/jnnp.67.2.209. View

17.

Salahudeen M, Duffull S, Nishtala P . Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015; 15:31. PMC: 4377853. DOI: 10.1186/s12877-015-0029-9. View

18.

Tune L . Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001; 62 Suppl 21:11-4. View

19.

Carnahan R, Lund B, Perry P, Pollock B, Culp K . The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006; 46(12):1481-6. DOI: 10.1177/0091270006292126. View

20.

Cross A, George J, Woodward M, Ames D, Brodaty H, Wolfe R . Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis. 2017; 60(2):349-358. DOI: 10.3233/JAD-170265. View